Clinical Long-Term Outcomes of Patient-Reported Outcomes in the Prospective Real-World Tofacitinib Response in Ulcerative Colitis Registry.

Hans H HerfarthAnita AfzaliMonika FischerDavid HudesmanMaisa AbdallaRobert McCabeBenjamin L CohenRyan C UngaroWill HarlanJohn HansonGauree G KonijetiSteven PolyakTimothy RitterBruce SalzbergJennifer SeminerioEmily EnglishXian ZhangMillie D Long

Published in: Clinical and translational gastroenterology (2024)

Tofacitinib is an effective maintenance therapy in patients with refractory UC. Dose reductions infrequently occurred during maintenance. Unmet needs in UC maintenance include improvement of urgency and psychosocial factors (NCT03772145).

Keyphrases

ulcerative colitis
patient reported outcomes
rheumatoid arthritis
mental health
stem cells
mesenchymal stem cells